Immune reconstitution inflammatory syndrome in tuberculous pleurisy and ulcerative colitis: a case report

Submitted: May 28, 2019
Accepted: July 24, 2019
Published: September 10, 2019
Abstract Views: 1358
PDF: 838
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

We present the case of a 46-year-old Caucasian male, affected by ulcerative colitis, who developed tuberculous pleurisy during immunosuppressive therapy; despite proper therapy, worsening of the radiological findings was observed. The case was discussed among an online group of Italian physicians and diagnosis of immune reconstitution inflammatory syndrome (IRIS) tuberculosis was established. Therapy was continued and full recovery was obtained. IRIS is a syndrome initially described during opportunistic infections in HIV infected after being placed in anti-retroviral therapy. It reveals itself through a wide variety of manifestations, including fever, lymphadenopathies, worsening of lung infiltrates, pleural or pericardial effusion, central nervous system involvement. Few data are available regarding the best therapeutic options. IRIS is an insidious and potentially serious complication of opportunistic infections in immunocompromised patients. The always wider diffusion of immunosuppressive therapies increases the number of patients at risk, therefore physicians need to be aware of the issue.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

Pleural Hub

How to Cite

Piffer, Federico, Guido Levi, Giampietro Marchetti, and Chiara Barbieri. 2019. “Immune Reconstitution Inflammatory Syndrome in Tuberculous Pleurisy and Ulcerative Colitis: A Case Report”. Monaldi Archives for Chest Disease 89 (3). https://doi.org/10.4081/monaldi.2019.1103.